<table data-role="table" id="table3" data-mode="columntoggle" class="ui-responsive table-stroke">
<tbody>
<tr>
<td><strong>Does the patient have chronic active hepatitis B virus (HBV) infection?</strong> TDF/FTC is active against HBV infection.
<ul class="single">
<li>Although not FDA-approved for the treatment of HBV, TDF/FTC may be used simultaneously as treatment for HBV infection and as PrEP.</li>
<li>Discontinuation of TDF/FTC requires close monitoring in patients with chronic hepatitis B infection because of the concern for rebound viremia.</li>
</ul>
<br />
<strong>Is the patient pregnant or attempting to conceive?</strong> PrEP may be one of several options to help protect the HIV seronegative partner from acquiring HIV infection in serodiscordant couples during attempts to conceive.
<ul class="single">
<li>If a woman is pregnant when starting PrEP or becomes pregnant while on PrEP, discuss the known risks and benefits of taking TDF/FTC during pregnancy (see bottom of 
<a href="step_info.jsp?info=inst6" data-inline="true" data-rel="dialog" data-transition="<%=transition%>" data-theme="c" class="recommendation">Table: Pre-Prescription: Patient Education Checklist</a>)</li>
<li>After discussing the potential risks of TDF/FTC, recommend continuation of PrEP during pregnancy or breastfeeding for those with ongoing risk for HIV.</li>
<li>Providers should report information regarding use of PrEP during pregnancy to the <a href="http://www.apregistry.com/" target="_blank">Antiretroviral Pregnancy Registry</a></li>
</ul>
<br />
<strong>Is the patient an adolescent?</strong>
<ul class="single">
<li>PrEP has not been studied in individuals younger than 18 years of age.</li>
</ul>
<br />
<strong>Is the patient taking concomitant nephrotoxic drugs or drugs that have interactions with TDF/FTC?</strong>
<ul class="single">
<li>Obtain a thorough medication history</li>
</ul>
<br />
<strong>Does the patient have osteopenia/osteomalacia/osteoporosis?</strong> There may be a risk of bone loss associated with tenofovir.
<ul class="single">
<li>Discuss risk of bone loss with individuals with pre-existing risk factors or demonstrated osteoporosis/osteomalacia/osteopenia.</li>
</ul>
</td>
</tr>
</tbody>
</table>